Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $13.60.

Several equities analysts have issued reports on the company. B. Riley Financial cut their price objective on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Orchestra BioMed in a research report on Thursday, May 14th. Barclays boosted their target price on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Wall Street Zen downgraded Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, March 12th.

Insider Transactions at Orchestra BioMed

In other news, insider Darren Sherman sold 15,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $3.87, for a total transaction of $58,050.00. Following the completion of the sale, the insider owned 1,184,327 shares in the company, valued at $4,583,345.49. The trade was a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Aryeh acquired 8,971 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $3.90 per share, with a total value of $34,986.90. Following the completion of the purchase, the director owned 117,453 shares of the company’s stock, valued at $458,066.70. This trade represents a 8.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 39,636 shares of company stock worth $158,081 over the last 90 days. 7.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Orchestra BioMed

A number of institutional investors have recently made changes to their positions in OBIO. 683 Capital Management LLC acquired a new position in shares of Orchestra BioMed during the fourth quarter worth about $847,000. China Universal Asset Management Co. Ltd. bought a new stake in Orchestra BioMed during the fourth quarter worth about $38,000. Daytona Street Capital LLC bought a new stake in Orchestra BioMed during the fourth quarter worth about $89,000. Holos Integrated Wealth LLC bought a new stake in Orchestra BioMed during the fourth quarter worth about $222,000. Finally, Knott David M Jr raised its holdings in Orchestra BioMed by 95.0% during the third quarter. Knott David M Jr now owns 195,000 shares of the company’s stock worth $484,000 after acquiring an additional 95,000 shares in the last quarter. 53.20% of the stock is owned by institutional investors and hedge funds.

Orchestra BioMed Trading Up 8.7%

Shares of OBIO opened at $4.24 on Friday. The stock has a fifty day moving average price of $4.03 and a two-hundred day moving average price of $4.19. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $5.42. The company has a market cap of $253.90 million, a price-to-earnings ratio of -4.37 and a beta of 0.50.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The firm had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.92 million. Analysts predict that Orchestra BioMed will post -1.47 EPS for the current fiscal year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.